Bailard’s Lipocine LPCN Stock Holding History

Bailard’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,880	Closed	-$31.9K	–	757
2022 Q4	$31.9K	Buy	+4,880	New	+$35.6K	﹤0.01%	699
2022 Q3	–	Sell	-4,376	Closed	-$60K	–	715
2022 Q2	$60K	Buy	+4,376	New	+$68.2K	﹤0.01%	671

Other funds holding LPCN

EWA

EP Wealth Advisors Torrance, California $20.3B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's LPCN Position: Q1 2023 in Review

Bailard sold out of Lipocine (LPCN) in Q1 2023, closing a stake of 4,880 shares — an estimated $31.9K sold.

Bailard first reported a position in LPCN in Q2 2022 and held it in 2 quarters. The position peaked at $60K in Q2 2022. 45 funds tracked by Wall St. Rank hold LPCN as of Q1 2023.

Bailard reported no remaining Lipocine position as of Q1 2023 after selling out during the quarter.
Bailard sold 4,880 Lipocine shares in Q1 2023, an estimated $31.9K.
Bailard first reported a position in Lipocine in Q2 2022 and held it in 2 quarters.
Bailard's Lipocine position peaked at $60K in Q2 2022.
45 funds tracked by Wall St. Rank held Lipocine as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.